BB-10901 in Treating Patients With Relapsed and/or Refractory Multiple Myeloma

Completed · Phase 1

Conditions studied: Multiple Myeloma

In brief

RATIONALE: Monoclonal antibodies, such as BB-10901, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. PURPOSE: This phase I trial is studying the side effects and best dose of BB-10901 in treating patients with relapsed and/or refractory multiple myeloma.

Key facts

Study ID

NCT00346255

Run by

ImmunoGen, Inc.

People needed

37

Starts

2005-04-01

Expected to finish

2011-03-01

Last updated by the study team

2013-04-23

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Cedars-Sinai Outpatient Cancer Center — Los Angeles, California, United States
• UCSF — San Francisco, California, United States
• Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute — Boston, Massachusetts, United States
• Roswell Park Cancer Institute — Buffalo, New York, United States
• St. Vincent's Comprehensive Cancer Center - Manhattan — New York, New York, United States
• Juan Domingo Peron 1500 - (B1629AHJ) Pilar — Buenos Aires, Buenos Aires, Argentina
• Gascon 450 - (C1181ACH) — Buenos Aires, Buenos Aires F.D., Argentina
• Av. Naciones Unidas 346. (X5016KEH)-Barrio Parque Velez Sarfield — Córdoba, Córdoba Province, Argentina

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.